Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476]

Affiliations

¹ Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe.
² Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe. Electronic address: nkiyota@med.kobe-u.ac.jp.
³ Cancer Treatment Center, Kansai Medical University Hospital, Hirakata.
⁴ Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama.
⁵ Department of Medical Oncology, Hyogo Cancer Center, Akashi.
⁶ Department of Head and Neck Surgery, Miyagi Cancer Center, Natori.
⁷ Department of Head and Neck Oncology, Miyagi Cancer Center, Natori.
⁸ Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
⁹ Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe.

Published Erratum

T Koyama et al. ESMO Open. 2024 Aug.

. 2024 Aug;9(8):103652.

doi: 10.1016/j.esmoop.2024.103652. Epub 2024 Jul 20.

¹ Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe.
² Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe. Electronic address: nkiyota@med.kobe-u.ac.jp.
³ Cancer Treatment Center, Kansai Medical University Hospital, Hirakata.
⁴ Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama.
⁵ Department of Medical Oncology, Hyogo Cancer Center, Akashi.
⁶ Department of Head and Neck Surgery, Miyagi Cancer Center, Natori.
⁷ Department of Head and Neck Oncology, Miyagi Cancer Center, Natori.
⁸ Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
⁹ Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe.

No abstract available

Figures

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H. Koyama T, et al. ESMO Open. 2024 Jun;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833968 Free PMC article. Clinical Trial.